Drug Profile
Research programme: cancer therapeutics - Celgene/NCI Cancer Centres
Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Abramson Cancer Center of the University of Pennsylvania; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The Herbert Irving Comprehensive Cancer Center; The Tisch Cancer Institute
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in Cancer in USA
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb